Eveliina Arponen1, Semi Helin1, Päivi Marjamäki2, Tove Grönroos2, Patrik Holm3, Eliisa Löyttyniemi4, Kjell Någren1, Mika Scheinin5, Merja Haaparanta-Solin2, Jukka Sallinen3, Olof Solin6. 1. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland. 2. MediCity/PET Preclinical Laboratory, Turku PET Centre, University of Turku, Turku, Finland. 3. Orion Pharma, Research and Development, Turku, Finland. 4. Department of Biostatistics, University of Turku, Turku, Finland. 5. Department of Pharmacology, Drug Development and Therapeutics, University of Turku, and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland; and. 6. Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland Accelerator Laboratory, Åbo Akademi University, Turku, Finland olof.solin@abo.fi.
Abstract
UNLABELLED: We report the development of a PET tracer for α2C adrenoceptor imaging and its preliminary preclinical evaluation. α2C adrenoceptors in the human brain may be involved in various neuropsychiatric disorders, such as depression, schizophrenia, and neurodegenerative diseases. PET tracers are needed for imaging of this receptor system in vivo. METHODS: High-specific-activity (11)C-ORM-13070 (1-[(S)-1-(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]-4-(3-(11)C-methoxymethylpyridin-2-yl)-piperazine) was synthesized by (11)C-methylation of O-desmethyl-ORM-13070 with (11)C-methyl triflate, which was prepared from cyclotron-produced (11)C-methane via (11)C-methyl iodide. Rats and mice were investigated in vivo with PET and ex vivo with autoradiography. The specificity of (11)C-ORM-13070 binding to α2 adrenoceptors was demonstrated in rats pretreated with atipamezole, an α2 adrenoceptor antagonist. The α2C adrenoceptor selectivity of the tracer was determined by comparing tracer binding in wild-type and α2A- and α2AC adrenoceptor knockout (KO) mice. (11)C-ORM-13070 and its radioactive metabolites in rat plasma and brain tissue were analyzed with radio-high-performance liquid chromatography and mass spectroscopy. Human radiation dose estimates were extrapolated from rat biodistribution data. RESULTS: The radiochemical yield, calculated from initial cyclotron-produced (11)C-methane, was 9.6% ± 2.7% (decay-corrected to end of bombardment). The specific activity of the product was 640 ± 390 GBq/μmol (decay-corrected to end of synthesis). The radiochemical purity exceeded 99% in all syntheses. The highest levels of tracer binding were observed in the striatum and olfactory tubercle of rats and control and α2A KO mice-that is, in the brain regions known to contain the highest densities of α2C adrenoceptors. In rats pretreated with atipamezole and in α2AC KO mice, (11)C tracer binding in the striatum and olfactory tubercle was low, similar to that of the frontal cortex and thalamus, regions with low densities of α2C adrenoceptors. Two radioactive metabolites were found in rat plasma, but only one of them was found in the brain; their identity was not revealed. The estimated effective radiation dose was comparable with the average exposure level in PET studies with (11)C tracers. CONCLUSION: An efficient method for the radiosynthesis of (11)C-ORM-13070 was developed. (11)C-ORM-13070 emerged as a potential novel radiotracer for in vivo imaging of brain α2C adrenoceptors.
UNLABELLED: We report the development of a PET tracer for α2C adrenoceptor imaging and its preliminary preclinical evaluation. α2C adrenoceptors in the human brain may be involved in various neuropsychiatric disorders, such as depression, schizophrenia, and neurodegenerative diseases. PET tracers are needed for imaging of this receptor system in vivo. METHODS: High-specific-activity (11)C-ORM-13070 (1-[(S)-1-(2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]-4-(3-(11)C-methoxymethylpyridin-2-yl)-piperazine) was synthesized by (11)C-methylation of O-desmethyl-ORM-13070 with (11)C-methyl triflate, which was prepared from cyclotron-produced (11)C-methane via (11)C-methyl iodide. Rats and mice were investigated in vivo with PET and ex vivo with autoradiography. The specificity of (11)C-ORM-13070 binding to α2 adrenoceptors was demonstrated in rats pretreated with atipamezole, an α2 adrenoceptor antagonist. The α2C adrenoceptor selectivity of the tracer was determined by comparing tracer binding in wild-type and α2A- and α2AC adrenoceptor knockout (KO) mice. (11)C-ORM-13070 and its radioactive metabolites in rat plasma and brain tissue were analyzed with radio-high-performance liquid chromatography and mass spectroscopy. Human radiation dose estimates were extrapolated from rat biodistribution data. RESULTS: The radiochemical yield, calculated from initial cyclotron-produced (11)C-methane, was 9.6% ± 2.7% (decay-corrected to end of bombardment). The specific activity of the product was 640 ± 390 GBq/μmol (decay-corrected to end of synthesis). The radiochemical purity exceeded 99% in all syntheses. The highest levels of tracer binding were observed in the striatum and olfactory tubercle of rats and control and α2A KO mice-that is, in the brain regions known to contain the highest densities of α2C adrenoceptors. In rats pretreated with atipamezole and in α2AC KO mice, (11)C tracer binding in the striatum and olfactory tubercle was low, similar to that of the frontal cortex and thalamus, regions with low densities of α2C adrenoceptors. Two radioactive metabolites were found in rat plasma, but only one of them was found in the brain; their identity was not revealed. The estimated effective radiation dose was comparable with the average exposure level in PET studies with (11)C tracers. CONCLUSION: An efficient method for the radiosynthesis of (11)C-ORM-13070 was developed. (11)C-ORM-13070 emerged as a potential novel radiotracer for in vivo imaging of brain α2C adrenoceptors.
Authors: Anna Krzyczmonik; Thomas Keller; Francisco R López-Picón; Sarita Forsback; Anna K Kirjavainen; Jatta S Takkinen; Aleksandra Wasilewska; Mika Scheinin; Merja Haaparanta-Solin; Franciszek Sączewski; Olof Solin Journal: Mol Imaging Biol Date: 2019-10 Impact factor: 3.488
Authors: Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-09 Impact factor: 9.236
Authors: Jussi Lehto; Jarkko Johansson; Lauri Vuorilehto; Pauliina Luoto; Eveliina Arponen; Harry Scheinin; Juha Rouru; Mika Scheinin Journal: Psychopharmacology (Berl) Date: 2015-04-29 Impact factor: 4.530
Authors: Pauliina Luoto; Sami Suilamo; Vesa Oikonen; Eveliina Arponen; Semi Helin; Jukka Herttuainen; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Mika Scheinin; Jere Virta; Kirsi Virtanen; Iina Volanen; Anne Roivainen; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-05-17 Impact factor: 9.236
Authors: Sjoerd J Finnema; Zoë A Hughes; Merja Haaparanta-Solin; Vladimir Stepanov; Ryuji Nakao; Katarina Varnäs; Andrea Varrone; Eveliina Arponen; Päivi Marjamäki; Katariina Pohjanoksa; Lauri Vuorilehto; Phebian A Babalola; Olof Solin; Sarah Grimwood; Jukka Sallinen; Lars Farde; Mika Scheinin; Christer Halldin Journal: Int J Neuropsychopharmacol Date: 2014-12-13 Impact factor: 5.176
Authors: Sjoerd J Finnema; Mika Scheinin; Mohammed Shahid; Jussi Lehto; Edilio Borroni; Benny Bang-Andersen; Jukka Sallinen; Erik Wong; Lars Farde; Christer Halldin; Sarah Grimwood Journal: Psychopharmacology (Berl) Date: 2015-04-30 Impact factor: 4.530